Rhumbline Advisers lifted its position in Diplomat Pharmacy Inc (NYSE:DPLO) by 6.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,929 shares of the company’s stock after purchasing an additional 7,800 shares during the period. Rhumbline Advisers’ holdings in Diplomat Pharmacy were worth $3,168,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brown Advisory Inc. purchased a new stake in shares of Diplomat Pharmacy in the first quarter worth $466,000. OLD National Bancorp IN increased its stake in shares of Diplomat Pharmacy by 24.9% in the second quarter. OLD National Bancorp IN now owns 15,791 shares of the company’s stock worth $404,000 after purchasing an additional 3,148 shares in the last quarter. Columbia Partners L L C Investment Management increased its stake in shares of Diplomat Pharmacy by 23.2% in the second quarter. Columbia Partners L L C Investment Management now owns 75,912 shares of the company’s stock worth $1,940,000 after purchasing an additional 14,286 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Diplomat Pharmacy by 17,568.5% in the second quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock worth $31,679,000 after purchasing an additional 1,232,427 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in shares of Diplomat Pharmacy in the second quarter worth $1,884,000. 81.04% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Jeffrey G. Park sold 1,695 shares of the firm’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $25.26, for a total transaction of $42,815.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 24.70% of the company’s stock.

A number of analysts have recently issued reports on the stock. ValuEngine raised shares of Diplomat Pharmacy from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. Leerink Swann reaffirmed an “outperform” rating and set a $33.00 target price on shares of Diplomat Pharmacy in a research note on Friday, June 22nd. Finally, Morgan Stanley raised their target price on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 3rd. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $26.64.

DPLO opened at $20.02 on Friday. The firm has a market cap of $1.49 billion, a P/E ratio of 25.02 and a beta of 1.12. Diplomat Pharmacy Inc has a fifty-two week low of $14.50 and a fifty-two week high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.91 and a quick ratio of 0.63.

Diplomat Pharmacy (NYSE:DPLO) last posted its earnings results on Monday, August 6th. The company reported $0.17 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.06). The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The business’s revenue was up 25.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.25 earnings per share. research analysts predict that Diplomat Pharmacy Inc will post 0.83 EPS for the current year.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Article: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.